1. THE REFERENCE FOR FIELD
VACCINATION

2. 2
WHEN SHOULD WE APPLY GUMBORO FIELD
VACCINATION?
WHY SHOULD I CHOOSE CEVAC ® IBD L?
WHAT SERVICES CAN WE PROVIDE AND WHAT
TOOLS ARE AVAILABLE?

3. 3
WHY CEVAC IBD L?
FEATURES AND BENEFITS
GUMBORO DISEASE
CEVAC IBD L : FEATURES AND BENEFITS
CEVA’S WINTERFIELD 2512
EARLY AND STRONG PROTECTION
SPREADING ABILITY
GUARANTEED IMMUNOCOMPETENCE
MONITORING AND DIAGNOSIS

4. IBDV Classification

5. Izovac Gumboro2/IZO
TAD Gumboro/TAD
Gumboro/OVEJERO
Izovac Gumboro3/IZO
Gumboral CT/MERIAL
Cu1/76DE
D78/GeneBank
BUR-706/MERIAL
Gallivac IBD/MERIAL
Poulvac/SOLVAY
GP82/CEVA
PBG98/76GB
P2/73DE
LIBDV/CEVA
Hipragumboro/HIPRA
Hipragumboro CH/80/HIPRA
Gumbovax/IVAZ
228E/GeneBank
Nobilis Gumboro 228E/INTERVET
GLS/87US
VarE/85US
2512/GeneBank
2512/CEVA
Univax/GeneBank
5
Distance 0.02
Tri-bio/IN
Bursa Blen/MERIAL
Gumbovax Plus/ISBI
Nobilis Gumboro D78/INTERVET
Tad Gumbovac Forte/LOHMANN
Delvax 228TC/Advance Pharma (INTERVET)
VarA/85US
Bursavac/GeneBank
STC/US
849VB/87BE
Dj/97HU
52/70GB
Miss
MB/ABIC
MB71/GeneBank
IBD vaccine/VENTRI
IV95/INDOVAX
BG/RIAH
PECS/97HU
MOH94/94HU
KABA/97HU
P3009
UK661/86GB
Soroa/ES
FS/97HU
OKYM/91JP
OKYMT/95JP
Bursine Plus/GeneBank
2512 group
STC group
Bursimune/BIOMUNE
Poulvac Bursine2/FORT DODGE
V877/K/GeneBank
00273/73Au
Bursavac live/GeneBank
Bursa Plus/FORT DODGE
D78
group
P2 group
228E
group
MB group
Lukert group
V877 group
PHYLOGENETIC TREE
IBD VACCINES
(Phylaxia, 2005)

6. CEVAC ® IBD L
Winterfield 2512 IBD strain.
Live freeze-dried -Intermediate Plus
type vaccine.
Produced on embryonated hen eggs
from SPF birds.
For the active immunization against
classical and very virulent Gumboro
disease.
By drinking water route at date
depending on the level of maternally
derived antibodies.

7. 7
FEATURES AND BENEFITS
CEVA’S WINTERFIELD 2512, THE ORIGINAL
VACCINE STRAIN
Vaccine strain originated from the first
case of IBD (Gumboro, Delaware, USA)
in 1960.
The methods and number of passages to
get the final product are exclusively part
of Ceva’s know-how.
Classical strain, providing protection
against all forms of challenge.

8. 8
Originally, W2512 is a
Sanofi Animal Health
inc. vaccine strain, the
ancestor of Ceva
Dr Winterfield provided
his strain to Sanofi AH
inc., which has been later
on partly sold to Merial
select, partly to Ceva;
master seeds stocks
were split between the
two companies
In the sales agreement,
Ceva was obliged to
abandon the “Blen”
name and to rename all
of its vaccines; Merial
select got the right to
keep Blen name
Important characteristics of isolates of a
strain of virus may vary considerably.

9. FEATURES AND BENEFITS

10. 10
QUICK REPLICATION CAPABILITY
Serology curve in 10-day old SPF birds (study no.1)
13
12
11
10
9
8
7
6
5
4
3
2
1
0
*
0 7 15 21 28
Days of the study
IBD VN titre (in log2)
Competitor 1 Competitor 2 Cevac IBD L Controls
*
*: statistical difference
60 SPF chicks with 10 days of age per group were vaccinated with CEVAC® IBD L and 2 competitors through ocular route. Serology
was carried out 7, 15, 21 and 28 days after vaccination to evaluate the immune response.

11. 11
QUICK REPLICATION CAPABILITY
Serology curve in 10-day old SPF birds (study no.1)
13
12
11
10
9
8
7
6
5
4
3
2
1
0
*
CEVAC® IBD L was the first to induce immune response. In
other words, CEVAC® IBD L is the fastest to replicate in the
bursa, as evidenced by the quickest and highest serological
conversion (7 days p-v).
0 7 15 21 28
Days of the study
IBD VN titre (in log2)
Competitor 1 Competitor 2 Cevac IBD L Controls
*
*: statistical difference
60 SPF chicks with 10 days of age per group were vaccinated with CEVAC® IBD L and 2 competitors through ocular route. Serology
was carried out 7, 15, 21 and 28 days after vaccination to evaluate the immune response.

12. 12
QUICK REPLICATION CAPABILTY
IBD Serology curve in 11-day old SPF birds (study no.2)
13
12
11
10
9
8
7
6
5
4
3
2
1
0
*
*
*: statistical difference
IBDvaccination
0 4 18 32
Days of the study
IBD VN titre (in log2)
Competitor 1 Competitor 2 Competitor 3 Competitor 4 Cevac IBD L Controls
60 SPF chicks with 11 days of age per group were vaccinated with CEVAC® IBD L and 4 competitors through ocular route. Serology
was carried out 7, 15, 21 and 28 days after vaccination to evaluate the immune response.

13. Vaccine-take and protection
Objective:
Evaluation of time needed for the development
of protection against vvIBDV infection,
after vaccine-take
(vvIBDV)
Phylaxia 2008: Vilmos Palya, Timea Tatar-Kis and Tamas
Mato
Scientific Support and Investigation

14. Vaccine-take and protection
Materials and Methods:
 Animals: 3 weeks old SPF chickens (at vaccination)
 Vaccine:
o Intermediate plus vaccine strain: W 2512 strain
1 dose per os
o Intermediate vaccine strain: D78 strain
1 dose per os
 Challenge strain:
o vvIBDV strain (D407/2/04TR) from Turkey
o Dose: 105.0 EID50/chicken
o Application: per os (200l)
 Challenges:
o Done at 2 (only W2512), 3, 4 and 5 days (only D78) post-vaccination
 Clinical observation done for 13 days post-challenge
(vvIBDV)

15. Vaccine-take and protection
Clinical protection:
• All vaccinated animals were protected against clinical signs or death
attributable to challenge (from the first challenge done at 2nd day p.v.-2512
strain or at 3rd day p.v.-D78 strain).
• 20-30% mortality was observed in control challenged groups. All other
chicks showed clinical signs of disease (anorexia, trembling, ruffled feathers
for 1-3 days). Further 10-40% of animals showed more serious signs:
listlessness, severe prostration.
• Each of the control challenged chickens showed severe bursal lesions
(histopathology) and low B:B index (0.20-0.25).
(vvIBDV)

16. Vaccine-take:
Sampling
date
Intermediate plus
(W2512)
Intermediate (D78)
Histopathology
(positive/total)
Serology
(pos/total)
Histopathology
(positive/total)
PCR
(pos/total)
Serology
(pos/total)
2nd day p.v. 5/5 1/5 NT
3rd day p.v. 5/5 3/5 4/5 4/5 0/5
4th day p.v. 5/5 4/5 3/5 4/5 0/5
5th day p.v. NT 4/5 5/5 1/5
NT: not tested
Vaccine-take and protection
(vvIBDV)

17. Vaccine-take and protection
Protection against challenge with vvIBDV:
Intermediate plus vaccine (W 2512 strain) CEVAC IBD L
Challenge
date
At challenge 4 days p.ch.
Histopathology
(positive/tested)
Serology
(pos./tested)
Histopathology
(protected/tested)
RFLP
(Vaccine/
vvIBDV)
2 days p.v. 5/5 1/5 5/5 5/0
3 days p.v. 5/5 3/5 5/5 3/0*
4 days p.v. 5/5 4/5 5/5 5/0
*Only 3 out of 5 PCR positive samples were tested by RFLP.
(vvIBDV)

18. Protection against challenge with vvIBDV:
Intermediate vaccine (D78 strain)
Challenge
date
At challenge 4 days p.ch.
Histop. PCR Serology
Histopathology RFLP
No
protection
Partial
protection Only
D78
Only
vvIBDV
<50%* ≥50%*
3 days p.v. 4/5 4/5 0/5 4/5 1/5 - - 5/5
4 days p.v. 3/5 4/5 0/5 4/5 - 1/5 1/5
(rev. D78)
4/5
5 days p.v. 4/5 5/5 1/5 3/5 1/5 1/5 - 5/5
* Percentage of protected follicules
Vaccine-take and protection
(vvIBDV)

19. VACCINE-TAKE AND PROTECTION (VVIBDV)
Conclusions:
 Both vaccines protected all animals from death/clinical signs as early
as 2 or 3 days post-vaccination.
 Vaccine-take was observed
• 2 days post-vaccination, and was complete (in 100% of chickens)
by 3 dpv in case of intermediate plus strain (2512)
• 3 days post-vaccination, and was not complete until 5 dpv in case
of intermediate strain (D78)
 The intermediate plus vaccine inhibited the replication of the
challenge virus in the bursa right after vaccine-take PROTECTION
AGAINST INFECTION!!
 The intermediate vaccine could not protect or only partially protected
the bursa from histopathological lesions caused by the challenge
virus

20. 20
WHY CEVAC IBD L?
FEATURES AND BENEFITS
THE BEST SOLUTION FOR DRINKING WATER VACCINATION
• Spreading ability
• Enhancing the vaccination coverage
• Homogenous protection

21. 21
SPREADING ABILITY
4
3
2
1
0
10 15 20 25 30 35 40 45 50 55
Age (days)
VN (log10)
Vaccinated
Contacts unvaccinated
Control
Cevac IBD L
Contacts Unvaccinated birds (birds not vaccinated but kept in contact with vaccinated ones) had the same level of seroconversion
than vaccinated birds.CEVAC® IBD L spreads from vaccinated to unvaccinated birds, providing full protection.

22. 22
GUARANTEED IMMUNOCOMPETENCE
Any IBD live vaccine MUST
colonize and replicate in the
bursa to provide protection.
Changes are normal and
reversible
Don’t compromise
immunocompetence
Don’t correlate with
performance
Billions of vaccinated birds ww
Used by all major producing
countries.
Tested according Ph.Eur
Outstanding income results
and performance recorded

23. Comparative Field Trials
Greece, 1998: Comparative trial on productive performance using Cevac IBD L
•Group 1 : 20,000 vaccinated at 14 days of age with CEVAC IBD L
•Group 2 : 30,000 vaccinated at 14 days of age with an intermediate plus competitor
•Slaughter age at 48 days for group 1 and at 47 days for group 2
Cevac IBD L group obtained better
productive performance than the
competitor in the field.

24. Comparative Field Trials
Poland, 1998: Mortality and serological response using Cevac IBD L.
5 broiler farms, 250,000 birds, on 2 to 4 cycles per farm.
One single administration of either CEVAC IBD L or competitor intermediate plus
vaccine at 14-17 days of age
Slaughter age in Farm 3 and 5: 45 days.
Cevac IBD L groups obtained lower mortality rates
and outstanding levels of ELISA titers at slaughter.

25. Comparative Field Trials
China, 1994: Profit using a single dose of Cevac IBD L.
•Arbor Acres Broilers.
•70,000 broilers in 3 houses vaccinated with CEVAC IBD L at 18 days
•90,000 in 4 houses vaccinated with a Gumboro vaccine produced by a local company at 18 and 30 days.
•Slaughter age at 57 – 58 days
Percentages of profit were significantly
better when Cevac IBD L was used.

26. Comparative Field Trials
Malaysia, 1994: Performance index using Cevac IBD L versus competitor.
13,000 Arbor Acres broiler chickens
Group 1 : 6,500 birds vaccinated with CEVAC IBD L at 12 days of age
Group 2 : 6,500 birds vaccinated with a intermediate plus competitor vaccine at 12 days of age
Slaughter at 45 days of age
Performance index was better in flocks
vaccinated with Cevac ® IBD L.

27. Comparative Field Trials
Thailand, 1998: Weight gain with Cevac IBD L in vvIBD experimental
challenge.
208 broilers vaccinated at D14 with Cevac IBD L and 3 other intermediate plus
vaccines
Birds challenged with vvIBD strain at D28
J.Sasepreeyajan et al: Relative virulence and efficacy of
intermediate plus IBD vaccines in broilers-1998. Division of
Avian Medicine. Bangkok, Thailand. Unpublished experimental
report
Cevac ® IBD L vaccinated animals have the highest rates of gain
weight after vvIBD experimental challenge.

28. Comparative Field Trials
Philippines, 1998: Comparative trial on Bursal lesion scores
after use of Cevac IBD L versus competitors.
•Comparative trial using 3 intermediate plus vaccines
•Age at vaccination 16 days
•Bursal scores at 10 days after vaccination.
The mean value of bursal lesion scores in vaccinated chickens was lower for Cevac IBD
L group than for the others intermediate plus vaccines, meaning better safety.

29. Comparative Field Trials
Mortality rates were lower
for the flocks vaccinated
with Cevac IBD L.
Morocco, 2000: Mortality rates in 4 flocks vaccinated with CEVAC IBD L
versus other intermediate plus vaccines.
•Group 1 : 4 flocks vaccinated with CEVAC IBD L
• Group 2 : 2 flocks vaccinated with another Intermediate Plus vaccine

30. Thank you